Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Lock-Up Expiration Hell Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (557)	12/19/2001 9:45:41 AM
From: tuck	Respond to of 1005

>>SAN DIEGO, Calif.--(BW HealthWire)--Dec. 19, 2001-- Applied Molecular Evolution, Inc. (AME) (Nasdaq: AMEV - news) today announced that it has agreed to optimize two protein therapeutics for Eli Lilly and Company (NYSE: LLY - news). The goal of the collaboration is to apply AME's proprietary AMEsystem(TM)directed molecular evolution technology to create optimized versions of an antibody as well as a non-antibody protein therapeutic for clinical development. Under the terms of the agreement, AME will receive an upfront signing fee, milestone payments, and royalties on future product sales. ``AME is excited to collaborate with Lilly, one of the world's leading pharmaceutical companies, on these two protein therapeutics,'' said William D. Huse, M.D., Ph.D., Chief Executive Officer and President of AME. ``This collaboration underscores AME's proven ability to optimize both antibody and non-antibody protein therapeutics to address life threatening diseases and significant unmet medical needs.'' ``We selected AME to optimize these important therapeutic proteins because of AME's unique experience and capabilities in engineering protein therapeutics. We, too, are excited about initiating this collaboration,'' said Thomas F. Bumol, Ph.D., Vice President, Research Technologies and Proteins, Eli Lilly and Company.<< snip Too bad BLUE HP was cash poor when AMEV was cheap. Cheers, Tuck

To: tuck who wrote (557)	1/16/2002 1:14:54 PM
From: tuck	Read Replies (1) \| Respond to of 1005

>>I suspect this run for INGN will run out of steam after this PR blitz. Best to swing trade these puppies. BLUE HP sells out: 1000 shares at $6.07, the bid as I type.<< Well, I got this one right, anyhow. It got bid up on progress, but at the end of the day, the market still loves to hate gene therapy and vaccine companies. Despite the added "value," INGN has given back most of its gains. BLUE HP still has hope for the gene therapy companies, and so begins nibbling on INGN again because it seems to be presenting an attractive entry point. 500 shares @ current ask of $4.85. Cheers, Tuck